Literature DB >> 7021122

Piroxicam: a review of its pharmacological properties and therapeutic efficacy.

R N Brogden, R C Heel, T M Speight, G S Avery.   

Abstract

Piroxicam is an N-heterocyclic carboxamide of 1,2 benzothiazine 1,1 dioxide with analgesic and anti-inflammatory activity. It has an extended half-life of about 40 hours and is suitable for once daily administration. Published studies indicate that piroxicam 20mg daily is comparable with aspirin 3 to 6g. indomethacin 75 to 150mg, phenylbutazone 400mg, naproxen 500mg, ibuprofen 1200 to 2400mg and diclofenac 75mg in rheumatoid arthritis. In osteoarthritis, piroxicam 20mg daily is comparable in efficacy with aspirin 2.6 to 3.9g, indomethacin 75mg, naproxen 500mg and fenbufen 600mg but is generally better tolerated than aspirin or indomethacin in patients with arthritic diseases. Piroxicam 20mg was at least as effective as indomethacin 75mg in a study in ankylosing spondylitis. As with other non-steroidal anti-inflammatory drugs gastrointestinal complaints are the most frequently reported side effects and their frequency and severity appears to be dose-related.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7021122     DOI: 10.2165/00003495-198122030-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  50 in total

1.  A double-blind comparison of piroxicam mane with piroxicam nocte in patients awaiting hip and/or knee joint replacement.

Authors:  C G Iwegbu; R J Patel; P McLeod; B Helal
Journal:  Eur J Rheumatol Inflamm       Date:  1981

2.  A double blind cross-over comparison of piroxicam and indomethacin in the treatment of rheumatoid arthritis.

Authors:  J Davies; A S Dixon; E F Ring
Journal:  Eur J Rheumatol Inflamm       Date:  1981

3.  Comparison of piroxicam with naproxen in rheumatoid arthritis: a double-blind, cross-over, multicentre study.

Authors:  O A Sydnes
Journal:  Eur J Rheumatol Inflamm       Date:  1981

4.  A double-blind, crossover, multicentre study of piroxicam and indomethacin in the treatment of rheumatoid arthritis.

Authors:  R Finstad
Journal:  Br J Clin Pract       Date:  1981-01

5.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  Piroxicam, a novel anti-inflammatory agent.

Authors:  E H Wiseman; Y H Chang; J G Lombardino
Journal:  Arzneimittelforschung       Date:  1976

7.  The topical anti-inflammatory effects of piroxicam in rodents.

Authors:  D L Larson; J G Lombardino
Journal:  Agents Actions       Date:  1980-06

8.  Piroxicam in the treatment of acute gout: a multicentre open study in general practice.

Authors:  J E Murphy
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

9.  The effect of piroxicam on platelet aggregation.

Authors:  B J Gaynor; J W Constantine
Journal:  Experientia       Date:  1979-06-15

10.  Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition.

Authors:  T J Carty; J S Stevens; J G Lombardino; M J Parry; M J Randall
Journal:  Prostaglandins       Date:  1980-05
View more
  20 in total

1.  Comparative bioavailability of two different rectal preparations of piroxicam in man.

Authors:  S Benkö; G Grézal; E Nagy; I Klebovich
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.

Authors:  L Martinez; J Sanchez; R Roser; J Garcia-Barbal; R Sagarra; A Bartlett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

3.  A re-evaluation of the HSA-piroxicam interaction.

Authors:  F Brée; S Urien; P Nguyen; P Riant; E Albengres; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

4.  Subacute hepatic necrosis induced by piroxicam.

Authors:  S M Lee; C J O'Brien; R Williams; S Whitaker; S R Gould
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

5.  Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).

Authors:  P Thürmann; S Harder; C M Kirchmaier
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults.

Authors:  A Darragh; A J Gordon; H O'Byrne; D Hobbs; E Casey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Double-blind preference and compliance multicentre study in osteoarthritis: once-a-day treatment.

Authors:  R Marcolongo; N Giordano; G P Bassi; R Giannini; C Borghi; B M Francucci; E Camarri; M Mordini; F Cocco; D Neri
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

9.  Piroxicam in human breast milk.

Authors:  M Ostensen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.